WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

DNTH past revenue growth

How has DNTH's revenue growth performed historically?
Company
-55.96%
Industry
144.63%
Market
17.55%
DNTH's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
DNTH's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

DNTH earnings and revenue history

Current Revenue
$2.8M
Current Earnings
-$43.6M
Current Profit Margin
-1,541.2%

DNTH Return on Equity

Current Company
-34.9%
Current Industry
-63.5%
Current Market
188%
DNTH's Return on Equity (-34.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when DNTH announces earnings.

DNTH Return on Assets

Current Company
-32.6%
Current Industry
2.9%
DNTH is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

DNTH Return on Capital Employed

Current Company
-25.65%
Current Industry
19.5%
DNTH has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

DNTH vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
DNTH$2.83M-$43.20M-$43.56M-55.96%N/A
MESO$7.25MN/A-$73.06M-14.93%N/A
HLVX$0.00-$119.02M-$123.57MN/AN/A
COGT$0.00-$188.82M-$192.41M-100.00%N/A
YMAB$84.82M-$24.94M-$21.43M+145.62%N/A
View Top Biotech Stocks

DNTH earnings dates

Next earnings date
May 13, 2024

Dianthus Therapeutics Earnings & Revenue FAQ

What were DNTH's earnings last quarter?

On Invalid Date, Dianthus Therapeutics (NASDAQ: DNTH) reported Q4 2023 earnings per share (EPS) of $8.95, up 177.36% year over year. Total Dianthus Therapeutics earnings for the quarter were -$10.56 million. In the same quarter last year, Dianthus Therapeutics's earnings per share (EPS) was -$11.57.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.

What was DNTH's earnings growth in the past year?

As of Q2 2024, Dianthus Therapeutics's earnings has grown year over year. Dianthus Therapeutics's earnings in the past year totalled -$43.56 million.

What is DNTH's earnings date?

Dianthus Therapeutics's earnings date is Invalid Date. Add DNTH to your watchlist to be reminded of DNTH's next earnings announcement.

What was DNTH's revenue last quarter?

On Invalid Date, Dianthus Therapeutics (NASDAQ: DNTH) reported Q4 2023 revenue of $457.00 thousand up 61.11% year over year. In the same quarter last year, Dianthus Therapeutics's revenue was $1.18 million.

What was DNTH's revenue growth in the past year?

As of Q2 2024, Dianthus Therapeutics's revenue has grown -55.96% year over year. This is 200.59 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Dianthus Therapeutics's revenue in the past year totalled $2.83 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.